Summary This study aimed to investigate the effect of tamoxifen on breast tumour levels of oestrogen and progesterone receptor (ER and PR) and proliferation as defined by the Ki67 antibody. A group of primary breast cancer patients was randomised to receive either tamoxifen (n = 59) or placebo (n = 44) treatment in the interval between clinic and surgery (median 21 days). Frozen (McGuire & Clark, 1983 .
It is well established that the measurement of breast tumour oestrogen and progesterone receptor (ER and PR) content is of considerable importance when evaluating likely response to endocrine therapy and prognosis (Sunderland & McGuire, 1991) . Response to anti-oestrogen therapy in human breast cancer is observed in approximately 50% of patients with ER-positive tumours who also have a better prognosis than those with ER-negative tumours. In those tumours that are ER-positive but endocrine-unresponsive, the receptor is thought to be defective and incapable of initiating a response to either oestrogen or anti-oestrogen (Sunderland & McGuire, 1991) .
The progesterone receptor (PR) is one of a number of proteins that are oestrogen-regulated via the ER and its presence should indicate a functional ER. Indeed, when PR status is examined in conjunction with ER, the prediction of response to anti-oestrogen therapy is improved to 75% of tumours (McGuire & Clark, 1983) . However, 25% of PR positive tumours do not respond to anti-oestrogens for reasons unknown and it is possible in these cases that PR may be being synthesised independently of ER, and therefore is not indicative of its function.
Progesterone receptor synthesis can be stimulated by the anti-oestrogen tamoxifen in human mammary tumour cells. This occurs not only in cultured MCF-7 cells (Horwitz et al., 1978) but also in breast cancer in vivo Noguchi et al., 1988) . As a predictive indicator of functional ER and responsiveness to endocrine therapy, measurement of PR before and during tamoxifen therapy has not been proven to be of more use than one measurement alone .
Tumour proliferative activity is also related to the prognosis of breast cancer and a negative correlation has been observed between presence of ER and/or PR and the growth fraction as measured by a variety of methods. These methods include measurement of thymidine incorporation (Meyer et al., 1977; , estimation of the S phase fraction by DNA flow cytometry (Olszewski et al., 1981; Raber et al., 1982) and immunohistological staining using the mouse monoclonal antibody Ki67 (McGurrin et al., 1987) which recognises a proliferation-associated nuclear antigen present in the late Gl, S, G2 and M, but not in the Go, phases of the cell cycle (Gerdes et al., 1983; 1984) . As the endpoint of antioestrogen action is inhibition of tumour cell proliferation, a more functional approach to predicting response would be the measurement of proliferative activity before and during administration of a short course of tamoxifen.
In the present study, we have used immunohistological methods to study breast tumour tissue before and after treatment with tamoxifen or a placebo in order to correlate and compare levels of expression of ER and PR with the proliferating cell-associated antigen defined by the monoclonal antibody Ki67, and with other histological data. The aim of the study was to elucidate the relationships between these factors before and after tamoxifen treatment in order to achieve a better prediction of response to endocrine treatment in individual patients. (Figure 2 ). There was a small but significant negative correlation between pre-treatment Ki67 LI and %ER using Spearman's non-parametric correlation coefficient (rho = -0.19, P <0.03), but no such correlation existed between %Ki67 LI and %PR. Effect of tamoxifen Tamoxifen or placebo was administered immediately after the first biopsy was taken and continued up until second biopsy at surgery, a median of 21 days later. The 59 patients who received tamoxifen had a median Ki67 LI of 5.6% in the first biopsy falling to 3.0% in the second biopsy ( Figure  3 ; P<0.001 by Wilcoxon's matched-pairs signed-rank test). The 44 patients who received placebo had a median Ki67 LI median values. The difference was of 5.4% in the first biopsy and 5.75% in the second (Figure  3 ), which was not significantly different by Wilcoxon's matched-pairs signed-rank test. No significant differences were seen when the median %Ki67 LI's of the first biopsy were compared between the two treatment groups, but there was a statistical difference when the post-treatment samples were compared (P = 0.002 by Mann-Whitney U-test). The median change in %Ki67 LI between first and second ,of +~ng- 10 .5% (range 0-100, n = 54) before tamoxifen treatment, and 21% (range 0-75, n = 54) after treatment (P = 0.497). In placebo group the pre-treatment median %ER was 0% (range 0-80, n = 41) and 14.5% (range 0-82, n = 41; P = 0.94) after treatment. The median %PR was 9.5% (range 0-100, n = 54) before, and 11 % (range 0-100, n = 54) after tamoxifen treatment (P = 0.233), whilst in the placebo group the pre-treatment median %PR was 0% (range 0-100, n = 42), and the post-treatment median %PR was 7.5% (range 0-75, n = 42; P = 0.25).
Patients and methods

Patients
Patient outcome
Disease-free survival was investigated over a short follow-up period (median = 18 months) and we found no difference in the rates of recurrence between patients whose tumours were either above or below the median %Ki67 LI in the first biopsy (data not shown). The change in %Ki67 LI (using the median change -1.8% as cut-off value) between the pre-and post-treatment biopsies in the tamoxifen treatment group also did not predict recurrence in our study.
Discussion
We have attempted to further elucidate the relationship between Ki67 LI, ER and PR content, prognosis and the likelihood of response to tamoxifen therapy by looking at changes in these parameters over a short period of treatment (median 21 days). There was a pronounced change in the median Ki67 LI in the group receiving tamoxifen which might be expected, as tamoxifen is highly anti-proliferative for human breast tumour cells in culture. However, this is the first time that these anti-proliferative effects have been demonstrated using the Ki67 antibody on human tumours in vivo.
The staining of the tumours with the Ki67 antibody to the proliferating cell-associated antigen and the scoring of the percentage of stained nuclei yields a labelling index (LI) that represents the number of cells in the GI, S, G2 and M phases of the cell cycle. Other workers have shown that the Ki67 LI is positively correlated with histological grade (Gerdes et al., 1986; McGurrin et al., 1987; Lelle et al., 1987; Barnard et al., 1987; Walker & Camplejohn, 1988; Raymond & Leong, 1989; Wrba et al., 1989) and negatively correlated with oestrogen receptor content determined both immunohistologically and biochemically Charpin et al., 1989; Bouzubar et al., 1989; Raymond & Leong, 1989; Wrba et al., 1989; Colley et al., 1989; Vollmer et al., 1989; Helin et al., 1989) and data obtained from our study are in agreement with these findings. Overall, the breast tumours in our study had a low mean Ki67 LI (7.0%) in comparison to other studies which report a range of mean Ki67 LI's from 7.2% to 22% (Wintzer et al., 1991) . However, our value was similar to that of Wrba et al. (1989) were somewhat higher scored the sections in a different manner, choosing to score, for instance, the areas of the section that were highly positive (Wintzer et al., 1991) . In other cases, there were less evident reasons for the disparity in mean Ki67 LI as the scoring criteria appeared similar to ours and it is assumed that there must be some methodological differences. The staining that was observed in our study appeared largely uniform throughout most tumour samples and this is confirmed by good correlation between the Trucut needle biopsies and the biopsies obtained at surgery in the placebo-treated group. We were unable to show induction of PR with tamoxifen treatment. It is possible that this is related to the period of time for which our patients were treated (median of 21 days) which is considerably longer than the 8 days used in our previous study or the 3 and 7 days used by Noguchi et al. (1988) . Noguchi et al. (1988) further showed that continuation of tamoxifen treatment to 14 days abolished stimulation of PR synthesis presumably because its initial agonist effects are soon reversed by its antagonism of oestrogen action. The absence of PR induction may also be related to the use of the immunocytochemical method of PR measurement which is only semiquantitative and ignores the intensity of staining.
Further analysis of the tamoxifen-treated group showed no relationship between a change in Ki67 LI and tumour steroid receptor content. One might expect the 'responsive' (4-Ki67 LI, n = 44) group to contain more receptor-positive (particularly PR) tumours than the 'unresponsive' (t Ki67 LI, n = 15) patients. However, receptor status was evenly distributed between the two groups and the medians of the receptor levels were also not significantly different. This lack of correlation may be a true reflection of the in vivo state during short-term tamoxifen treatment, but conflicts with the reported 75% response rate in ER positive PR positive tumours compared with a 10% response rate in ER negative PR negative tumours (McGuire & Clark, 1983) . The disparity may be due to heterogeneity in receptor status within each carcinoma (Osborne, 1985; Alanko, 1985; Van Netten et al., 1986; Howell et al., 1987b) , and between the Trucut and surgical biopsies (Jackesz et al., 1985; Young et al., 1985) . This could well have influenced our study as receptor staining and Ki67 staining were not performed on adjacent histological sections as receptors are stained routinely in the laboratory when breast tumour specimens arrive, whereas the Ki67 antibody staining was performed at a later date. It may well be that Ki67 staining (i.e. proliferation) varies throughout a tumour in a similar fashion to steroid receptor levels and that if staining were performed on adjacent sections a correlation could perhaps be seen.
We also investigated disease-free survival over a short follow-up period (median = 18 months). We found no difference in the rates of recurrence between patients whose tumours were either above or below the median Ki67 LI in the first biopsy. The change in Ki67 LI (using the median change as cut-off value) between the pre-and post-treatment biopsies in the tamoxifen treatment group also did not predict recurrence in our study. However, longer follow-up may reveal Ki67 LI to be a prognostic factor as shown in the study by Wintzer et al. where patients were followed up for a median of 37 months. Using the median as cut-off point, they found significantly different curves for disease-free survival, but Ki67 LI was of independent prognostic value only if a higher cut-off level was selected.
To our knowledge, this is the first study in which shortterm tamoxifen treatment of breast tumour in vivo has been shown to lead to a significant fall in proliferation as measured by Ki67 immunostaining. This change in proliferative status was not correlated with other indicators of hormone responsiveness such as receptor status. There was no relationship between Ki67 LI and recurrence rates of all patients or between changes in Ki67 LI from first to second biopsy and recurrence rates in the tamoxifen treated group, although the follow-up period is short. The reduction in Ki67 immunostaining in tamoxifen-treated patients suggests that the antibody Ki67 may prove to be of value in determining response for both established therapies such as tamoxifen treatment and trial therapies, for example when studying the efficacy of the new, pure antioestrogens.
